- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Promising Role of Immunotherapy in Lung Cancer Treatment Emphasized at ELCC 2014
In the treatment of lung cancer, immunotherapy has come of age and is here to stay expert says at the 4th European Lung Cancer Conference.
A new era of lung cancer therapy is close to dawning, using drugs that can prevent tumour cells from evading the immune system, experts have said at the 4th European Lung Cancer Congress.
Annals of Oncology
For decades, scientists and doctors thought immunotherapy — treatments that harness the immune system to fight a disease – was of marginal benefit in lung cancer, says ESMO spokesperson Jean-Charles Soria, Institute Gustave Roussy in Paris, France and Editor-in-Chief of .
However a new class of drugs known as “immunocheckpoint regulators” have shown huge potential, Soria says. New data on several of these drugs were presented at the conference.
Read the entire press release here:
http://bit.ly/1g2oeOF Source: European Society for Medical Oncology
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Texas Oncology to Roll Out Canopy for ePROs After Head-to-Head Pilot
March 18th 2025Debra Patt, MD, PhD, MBA, executive vice president of Public Policy and Strategy for Texas Oncology, said the practice received positive feedback from nurses and patients during a pilot that concluded in February.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
